ClinicalTrials.gg
CompletedNCT00161876Updated May 21, 2015

FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years

A Phase 3 interventional study of Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) in Encephalitis, Tick-borne, sponsored by Pfizer. Completed at 8 sites in Poland. Open to participants aged 16 Years to 66 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-21.

Sponsored by Pfizer · Phase 3 and Interventional

Phase
Phase 3
Study type
Interventional
Enrollment
3,973
Allocation
Non-randomized
Ages
16 Years to 66 Years
Sex
All
01

Study summary

The aim of this study is to evaluate the safety of the third vaccination with FSME-IMMUN NEW in all volunteers who received both vaccinations in Baxter study 208 (safety study of FSME IMMUN NEW and ENCEPUR in healthy volunteers aged 16 to 65 years).

02

Conditions studied

  • Encephalitis, Tick-borne

Keywords

  • tick-borne encephalitis
03

In context

Encephalitis, Tick-Borne

51 studies on the registry are indexed under Encephalitis, Tick-Borne; 9 are open to participants now.

This study's enrollment of 3,973 is above the median of 192 across 32 interventional studies indexed under Encephalitis, Tick-Borne.

Browse Encephalitis, Tick-Borne studies →

Lead sponsor

Pfizer is the lead sponsor of 3,334 studies on the registry; 149 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 391 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 66 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Received two vaccinations during the course of Baxter study 208
  • Understand the nature of the study, agree to its provisions and give written
  • For volunteers under 18 years of age - written informed consent of the parents/legal guardian is given

Exclusion criteria

Exclusion Criteria:

  • None.

Volunteers assessed for eligibility to receive a third vaccination.

Eligibility to receive third vaccination:

  • ELISA value > 126 VIE U/ml before the first TBE vaccination in Baxter study 208
  • Not clinically healthy, (i.e. the physician would have reservations vaccinating with FSME-IMMUN NEW outside the scope of a clinical trial)
  • Have already been administered a third TBE vaccination elsewhere since receiving the two vaccinations in Baxter study 208
  • Have had an allergic reaction to one of the components of the vaccine since the last vaccination in Baxter study 208
  • Suffer from a disease (e.g. disease) or are undergoing a form of treatment (e.g. systemic , chemotherapeutics) that can be expected to influence immunological functions
  • Have a known or suspected problem with drug or alcohol abuse (> 4 liters wine / week or equivalent dose of other alcoholic beverages)
  • Have received banked human blood or immunoglobulins within one month of study entry
  • Are known to have become infected with (a special HIV test is not required for the purpose of the study) since the last visit of study 208
  • Have had a vaccination against yellow fever and / or Japanese B-encephalitis since the last visit in study 208
  • Have received an new drug within 6 weeks prior to study start
  • Have a positive pregnancy test at the first medical examination (for females capable of bearing children)
  • Do not agree to employ adequate measures for the duration of the study (for females capable of bearing children)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
3,973 participants
06

Study locations

8 sites
  • Zespol Opieki Zdrowotnej w Debicy
    Debica, 33-200, Poland
  • Wojewodzki Szpital Dzieciecy Oddzial Obserwacyjno - Zakazny A
    Kielce, 25-381, Poland
  • "Atopia" Diagnostyka i Leczenie Chorob Alergicznych i Ukladu Oddechowego
    Krakow, 30-018, Poland
  • Przedsiebiorstwo Uslug Medycznych "Centrum Medyczne Nowa Huta"
    Krakow, 30-969, Poland
  • Szpital Jana Pawla II Oddzial Neuroinfekcji
    Krakow, 31-202, Poland
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Oddzial Pediatryczny
    Lubartow, 21-100, Poland
  • PANTAMED sp. z o.o.
    Olsztyn, 10-461, Poland
  • Oddzial Chorób Zakaznych Specjalistyczny Szpital im. E. Szczeklika
    Tarnow, 33-100, Poland
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 21, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00161876
Lead sponsor
Pfizer
First posted
Sep 13, 2005
Start date
May 2002
Completion
Aug 2002
Last update
May 21, 2015

Study contacts

Jerzy Romaszko, MD
principal investigator · PANTAMED sp. z o o.
Jerzy Brzostek, MD
principal investigator · Zespol Opieki Zdrowotnej w Debicy
Jerzy Dziduch, MD
principal investigator · Samodzielny Publiczny Zaklad Opieki Zdrowotnej Oddzial Pediatryczny
Krystyna Jurowska, MD
principal investigator · Przedsiebiorstwo Uslug Medycznych "Centrum Medyczne Nowa Huta"
Marian Patrzalek, MD
principal investigator · Wojewodzki Szpital Dzieciecy Oddzial Obserwacyjno - Zakazny A
Krzysztof Sladek, MD
principal investigator · "Atopia" Diagnostyka i Leczenie Chorob Alergicznych i Ukladu Oddechowego
Ryszard Konior
principal investigator · Szpital Jana Pawla II Oddzial Neuoinfekcji
Grazyna Zawada-Skrobisz, MD
principal investigator · Oddzial Chorob Zakaznych Specjalistyczny Szpital, Tarnow
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tick-borne encephalitis vaccine

Start the discussion